Hims & Hers Health saw a 24% stock surge today following its strategic acquisition of Trybe Labs, a company specializing in at-home lab testing solutions. This marks a significant move toward enhancing personalized healthcare, allowing Hims & Hers to integrate at-home diagnostics into its telehealth platform.
The acquisition will enable comprehensive body testing, including at-home blood sample collection, giving patients greater control over their health insights. This initiative aligns with the company's mission to detect potential health risks early and support tailored treatment plans across key clinical areas such as low testosterone, menopause, and perimenopausal health management.
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile appAI and Telehealth
Hims & Hers is introducing a minimally invasive blood collection method using a blood lancet, which offers an alternative to traditional needles and dried blood spot cards. This innovation allows users to conveniently monitor: Hormone levels, cardiac risk factors, stress markers, cholesterol and liver function and thyroid and prostate health
The real-time health data collected from these tests will not only empower customers with deeper health insights but also play a crucial role in the company's AI-driven initiatives, including MedMatch by Hims & Hers—an advanced AI-powered healthcare platform designed to deliver customized, high-quality, and affordable care.
Hims & Hers noted that enhanced access to lab testing data will help refine personalized treatment plans, bridging the gap between traditional clinical visits and remote healthcare solutions.
While financial terms of the acquisition remain undisclosed, Hims & Hers confirmed that the deal was fully funded using available cash reserves. The company is set to launch its at-home testing services over the next year, further solidifying its position as a leader in innovative, tech-driven healthcare solutions.
This expansion into at-home lab testing underscores Hims & Hers’ commitment to reshaping the future of personalized medicine, offering accessible, data-driven, and AI-enhanced healthcare services. Hims & Hers valuation as for now looks really high, however markets expect that company will have a much more healthcare market share.
HIMS.US (D1)
The company shares surge almost 190% YTD and 650% YoY, driven by AI implementation across the personal health services.
Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
